Potential CYP2C9‐mediated drug–drug interactions in hospitalized type 2 diabetes mellitus patients treated with the sulphonylureas glibenclamide, glimepiride or glipizide

@article{Tirkkonen2010PotentialCD,
  title={Potential CYP2C9‐mediated drug–drug interactions in hospitalized type 2 diabetes mellitus patients treated with the sulphonylureas glibenclamide, glimepiride or glipizide},
  author={Tuire Tirkkonen and Pekka Heikkil{\"a} and Risto K. Huupponen and Kari Laine},
  journal={Journal of Internal Medicine},
  year={2010},
  volume={268}
}
Abstract.  Tirkkonen T, Heikkilä P, Huupponen R, Laine K (University of Turku; Turku University Hospital; and StatFinn Ltd; Turku, Finland). Potential CYP2C9‐mediated drug–drug interactions in hospitalized type 2 diabetes mellitus patients treated with the sulphonylureas glibenclamide, glimepiride or glipizide. J Intern Med 2010; 268: 359–366. 

Pharmacokinetic interactions of selective serotonin reuptake inhibitors with other commonly prescribed drugs in the era of pharmacogenomics

The significance of drug interactions in the era of pharmacogenomics is discussed to underline the need for using information on both genotype and drug interactions towards implementing better clinical outcomes through personalized medicine.

Clinically and pharmacologically relevant interactions of antidiabetic drugs

  • M. MayC. Schindler
  • Medicine, Biology
    Therapeutic advances in endocrinology and metabolism
  • 2016
Although metformin has a very low interaction potential, caution is advised when drugs that impair renal function are used concomitantly, and Incretin mimetics and sodium–glucose cotransporter-2 (SGLT-2) inhibitors are recommended as an ideal combination partner from the clinical–pharmacologic point of view.

Hypoglycemia possibly caused by CYP2C9-mediated drug interaction in combination with bucolome: a case report

The possibility of hypoglycemia due to drug interactions should be considered by physicians, when bucolome is included to enhance the effect of warfarin, in patients taking glimepiride.

CYP2C metabolism of oral antidiabetic drugs - impact on pharmacokinetics, drug interactions and pharmacogenetic aspects

This review focuses on the effect of CYP2C enzymes on metabolism of sulphonylureas, meglitinides, and thiazolidinediones discussing their impact on pharmacokinetics, drug interactions and toxicological profiles.

Drug–Drug Interactions with Sodium-Glucose Cotransporters Type 2 (SGLT2) Inhibitors, New Oral Glucose-Lowering Agents for the Management of Type 2 Diabetes Mellitus

  • A. Scheen
  • Medicine, Biology
    Clinical Pharmacokinetics
  • 2014
Potential DDIs in patients with type 2 diabetes receiving chronic treatment with an SGLT2 inhibitor deserve further attention, especially in individuals treated with several medications or in more fragile patients with hepatic and/or renal impairment.

Population pharmacokinetics of carvedilol enantiomers and their metabolites in type-2 diabetes and healthy subjects

This paper presents a meta-modelling study comparing the models used in the GlaxoSmithKline Clinical Pharmacology Modelling & Simulation and the real-world clinical practice, which shows real-time changes in the response of the immune system to drug antagonists.

Effects of Type 2 Diabetes Mellitus in Patients on Treatment With Glibenclamide and Metformin on Carvedilol Enantiomers Metabolism

The pharmacokinetics of carvedilol enantiomers and their metabolites OHC and DMC did not differ between the groups, however, the AUC values of the DMC enantiomer were lower in the type 2 diabetes mellitus patients than in the healthy volunteers (DDI and no DDI).

Study on the Effect of Three CYP2C9 Variants on Drug–Drug Interaction Related to Six Drugs In Vitro by LC–MS/MS Method

The results could offer effective guidelines for co-administration of these six drugs with various CYP2C9 substrates in individuals carrying variant CYP 2C9 alleles, and broaden the application area of LC–MS/MS.

References

SHOWING 1-10 OF 28 REFERENCES

Evaluation of potential losartan‐phenytoin drug interactions in healthy volunteers *

Phenytoin, a cytochrome P450 (CYP) 2C9 substrate, has a narrow therapeutic index and nonlinear pharmacokinetics. Therefore there is the potential for significant concentration‐related adverse effects

Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers

It is hypothesized that glyburide may be a substrate of cytochrome P450 2C9 (CYP2C9), an enzyme that has two low‐activity amino acid variants‐Arg144Cys and Ile359Leu and the impact of these polymorphisms on glyBuride pharmacokinetics and the effects on insulin and glucose concentrations is explored.

Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes

The effects of genetic polymorphisms of cytochrome P450 (CYP) 2C9 on the pharmacokinetics of glyburide (INN, glibenclamide) and glimepiride, two widely used sulfonylurea antidiabetic drugs, are investigated.

Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents.

Findings suggest that among other factors, individuals with genetically determined low CYP2C9 activity are at an increased risk of sulphonylurea-associated severe hypoglycaemia, and genotyping might be a tool for the better prediction of adverse effects caused by oral hypglycaemic agents.

Effect of Genetic Polymorphisms in Cytochrome P450 (CYP) 2C9 and CYP2C8 on the Pharmacokinetics of Oral Antidiabetic Drugs

Pharmacogenetic variability plays an important role in the pharmacokinetics of oral antidiabetic drugs; however, to date, the impact of this variability on clinical outcomes in patients is mostly unknown and prospective studies on the medical benefit of CYP genotyping are required.

Drug Interactions of Clinical Importance with Antihyperglycaemic Agents

Triple therapy with the addition of a thiazolidinedione to the metformin-sulphonylurea combination has been recently evaluated and allows glucose targets to be reached before insulin therapy is considered, and appears to be safe, with no deleterious drug-drug interactions being reported.

Effects of rifampin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide

To study the effects of rifampin on the pharmacokinetics and pharmacodynamics of glyburide (INN, glibenclamide) and glipizide, 2 sulfonylurea antidiabetic drugs.

Drug Interactions of Clinical Importance with Antihyperglycaemic Agents : An Update.

Triple therapy with the addition of a thiazolidinedione to the metformin-sulphonylurea combination has been recently evaluated and allows glucose targets to be reached before insulin therapy is considered, and appears to be safe, with no deleterious drug-drug interactions being reported.